Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Prostatic Neoplasms 53Brain Neoplasms 51Carcinoma, Non-Small-Cell Lung 49Lung Neoplasms 30Neoplasm Metastasis 29Breast Neoplasms 23Pancreatic Neoplasms 16Melanoma 15Carcinoma, Renal Cell 14Carcinoma, Hepatocellular 13Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Kidney Neoplasms 5Liver Neoplasms 4Glioblastoma 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Spinal Cord Neoplasms 3Sarcoma 3Prostate Cancer Metastatic 3NSCLC 3Meningioma 3Lymphatic Metastasis 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

Radiotherapy, Conformal 2Radiotherapy 2Paclitaxel 2Nivolumab 2Carboplatin 2veliparib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Platinum 1Metformin 1Mastectomy, Segmental 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Docetaxel 1Disulfides 1Cisplatin 1CTLA-4 Antigen 1Bevacizumab 1Anterior Temporal Lobectomy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Bronchiolo-Alveolar × Radiosurgery × 1 year × Clear all
NCT03110978 2026-04-16

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
140 enrolled
EndocrineThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡